APLS APELLIS PHARMACEUTICALS INC

Ownership history in ORBIMED ADVISORS LLC  ·  22 quarters on record

This page tracks every 13F SEC filing in which ORBIMED ADVISORS LLC reported a position in APELLIS PHARMACEUTICALS INC (APLS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.5% (2023 Q2)
Avg. % of fund
0.63%
First filed
2018 Q4
Last filed
2025 Q4
Quarters held
22
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 2,429,868 +2,179,868 +871.9% 1.25% $61.0M $25.12
2025 Q3 REDUCED 250,000 -2,073,368 -89.2% 0.13% $5.7M $22.63
2025 Q3 ADDED 2,323,368 +2,273,368 +4546.7% 1.24% $52.6M $22.63
2025 Q2 REDUCED 50,000 -1,432,300 -96.6% 0.02% $866K $17.31
2025 Q2 ADDED 1,482,300 +50,000 +3.5% 0.64% $25.7M $17.31
2025 Q1 ADDED 1,432,300 +161,900 +12.7% 0.75% $31.3M $21.87
2024 Q3 REDUCED 1,270,400 -32,400 -2.5% 0.67% $36.6M $28.84
2024 Q2 ADDED 1,302,800 +5,000 +0.4% 0.99% $50.0M $38.36
2024 Q1 ADDED 1,297,800 +1,147,800 +765.2% 1.40% $76.3M $58.78
2024 Q1 REDUCED 150,000 -772,200 -83.7% 0.16% $8.8M $58.78
12 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    APLS price (monthly, adj. close)
← Back to ORBIMED ADVISORS LLC Holdings